1.39
-0.026(-1.83%)
Currency In USD
| Previous Close | 1.42 |
| Open | 1.44 |
| Day High | 1.44 |
| Day Low | 1.38 |
| 52-Week High | 1.89 |
| 52-Week Low | 0.71 |
| Volume | 186,439 |
| Average Volume | 1.09M |
| Market Cap | 161.58M |
| PE | 2.53 |
| EPS | 0.55 |
| Moving Average 50 Days | 1.39 |
| Moving Average 200 Days | 1.14 |
| Change | -0.03 |
If you invested $1000 in Coherus Oncology, Inc. (CHRS) 10 years ago, it would be worth $66.16 as of January 02, 2026 at a share price of $1.394. Whereas If you bought $1000 worth of Coherus Oncology, Inc. (CHRS) shares 5 years ago, it would be worth $82.44 as of January 02, 2026 at a share price of $1.394.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
GlobeNewswire Inc.
Nov 07, 2025 2:00 PM GMT
– CHS-114 demonstrated robust and selective depletion of CCR8+ Tregs as well as favorable immune remodeling in tumor tissue from head and neck squamous cell carcinoma (HNSCC) patients – – CHS-114 administration resulted in selective depletion of CCR8
Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer
GlobeNewswire Inc.
Nov 06, 2025 6:54 PM GMT
– Responsible for Corporate Development, Investor Relations, Government Affairs – REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that Arvind Sood has joined the Company as Chief Strate
Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025
GlobeNewswire Inc.
Oct 30, 2025 12:30 PM GMT
REDWOOD CITY, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its third quarter 2025 financial results will be released after market close on Thursday, November 6, 2025. Starting at 5:00 p.m. Ea